In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds

Naoto Watamura, Martha Foiani, Sumi Bez, Mathieu Bourdenx, Alessia Santambrogio, Claire Frodsham, Elena Camporesi, Gunnar Brinkmalm, Henrik Zetterberg, Saisha Patel, Naoko Kamano, Mika Takahashi, Javier Rueda‐Carrasco, Loukia Katsouri, Stephanie L. Fowler, Emir Turkes, Shoko Hashimoto, Hiroki Sasaguri, Takashi Saito, Aditi Islam, Seico Benner, Toshihiro Endo, Katsuji Kobayashi, Chiho Ishida, Michele Vendruscolo, Masahito Yamada, Karen Duff, Takaomi C. SaidoNature Neuroscience 2024 · DOI

Abstract

Tau pathology is a hallmark of several neurodegenerative diseases, including frontotemporal dementia and Alzheimer's disease. However, the sequence of events and the form of tau that confers toxicity are still unclear, due in large part to the lack of physiological models of tauopathy initiation and progression in which to test hypotheses. We have developed a series of targeted mice expressing frontotemporal-dementia-causing mutations in the humanized MAPT gene to investigate the earliest stages of tauopathy. MAPT<sup>Int10+3G>A</sup> and MAPT<sup>S305N;Int10+3G>A</sup> lines show abundant hyperphosphorylated tau in the hippocampus and entorhinal cortex, but they do not develop seed-competent fibrillar structures. Accumulation of hyperphosphorylated tau was accompanied by neurite degeneration, loss of viable synapses and indicators of behavioral abnormalities. Our results demonstrate that neuronal toxicity can occur in the absence of fibrillar, higher-order structures and that tau hyperphosphorylation is probably involved in the earliest etiological events in tauopathies showing isoform ratio imbalance.

Introduction: The Search for the Toxic Tau Species

In neurodegenerative diseases like Alzheimer’s and Frontotemporal Dementia (FTD), the tau protein shifts from a soluble state to insoluble, fibrillar "tangles." For decades, researchers have debated the nature of the "toxic species": is it the large tangles, smaller "seeds" that spread from cell to cell, or soluble modified tau? This research challenges the long-standing assumption that large protein aggregates are the primary drivers of neurodegeneration.

A major hurdle has been the lack of physiological models. Most mouse models overexpress tau at levels 5–10 times higher than normal, which can cause artifacts. This study addresses the need for a "physiological" model—mice that express human tau at normal levels with specific FTD-causing mutations—to map the earliest events of the disease.

Figure 1: Genetic targeting of the humanized MAPT locus using sgRNAs for specific FTD mutations.

Methods: Precision Engineering of Humanized Models

The team utilized several cutting-edge techniques to ensure their model was as human-relevant as possible:

  • Base Editing (BE3): Instead of traditional transgenic methods, they used third-generation Base Editors to introduce specific point mutations (Int10+3 and S305N) directly into the humanized MAPT gene of knock-in (KI) mice.
  • Super-Resolution Microscopy (Airyscan): To detect subtle synapse loss, they used 3D super-resolution imaging to count the colocalization of pre-synaptic (synaptotagmin/vGLUT1) and post-synaptic (Homer1) markers.
  • Seeding Assays (RT-QuIC & Biosensors): They used Real-Time Quaking-Induced Conversion (RT-QuIC) and FRET-based biosensor cell lines to determine if the tau in these mice had the "prion-like" ability to induce misfolding in other tau molecules.
  • Automated Behavior (IntelliCage): They employed an automated home-cage system to monitor complex behaviors like behavioral flexibility, impulsivity, and apathy over weeks, reducing the stress and variability of manual testing.
Figure 2: Overview of the base editing pipeline and validation of the humanized MAPT knock-in mouse models.

Datasets and Model Characterization

The study introduces several new mouse lines:

  • $MAPT^{Int10+3}$: Mimics a human intronic mutation that shifts the ratio of tau isoforms.
  • $MAPT^{S305N;Int10+3}$: A double mutant line with higher levels of 4-repeat (4R) tau.
  • Controls: Standard humanized MAPT KI mice and wild-type (WT) mice.
  • Human Tissue: Post-mortem brain samples from FTD and Alzheimer's patients were used as benchmarks for pathology and seeding activity.

Key Insights

Toxicity Without Tangles

The most striking finding is that the mutant mice developed significant neurite degeneration and synapse loss despite being negative for Gallyas silver staining (a marker for tangles) and showing zero seeding activity. This proves that "seeds" and fibrils are not required for tau-mediated toxicity.

The 3R:4R Ratio as a Trigger

Human tau exists in isoforms with either three (3R) or four (4R) microtubule-binding repeats. The mutations used here shift the balance toward 4R tau (98–99% 4R-tau in mutants vs. ~50% in controls). This imbalance alone was sufficient to trigger hyperphosphorylation and neurodegeneration.

Soluble p-tau as the Culprit

The researchers found abundant hyperphosphorylated tau (p-tau) distributed diffusely in the hippocampus and entorhinal cortex. This soluble p-tau correlates with the onset of behavioral deficits, pointing to it as the likely toxic species. The mice showed "behavioral variant FTD" (bvFTD) symptoms, including increased impulsivity and apathy.

Key Results

  • Synapse Loss: Super-resolution imaging revealed a significant reduction (~25%) in viable synapses in the hippocampus and entorhinal cortex of 16-month-old mutant mice.
  • Behavioral Deficits: Mutant mice showed a significant increase in "premature responses" (impulsivity) and a reduced preference for high-effort rewards (apathy).
  • Biochemical Confirmation: Despite clear neurodegeneration, sucrose gradient fractionation and RT-QuIC confirmed that the tau remained largely monomeric and lacked higher-order fibrillar structure even at 24–30 months of age.

Limitations and Future Work

The authors acknowledge that while they see toxicity without fibrils, they cannot rule out that fibrils might form if the mice lived significantly longer (beyond 30 months). Furthermore, while they identified hyperphosphorylation as a key correlate of toxicity, the exact molecular mechanism—how specifically p-tau disrupts the synapse—remains to be fully elucidated. These mice provide a platform to test interventions that target tau phosphorylation or isoform splicing at the very earliest stages of disease.

Summary updated

Abstract

Tau pathology is a hallmark of several neurodegenerative diseases, including frontotemporal dementia and Alzheimer's disease. However, the sequence of events and the form of tau that confers toxicity are still unclear, due in large part to the lack of physiological models of tauopathy initiation and progression in which to test hypotheses. We have developed a series of targeted mice expressing frontotemporal-dementia-causing mutations in the humanized MAPT gene to investigate the earliest stages of tauopathy. MAPT<sup>Int10+3G>A</sup> and MAPT<sup>S305N;Int10+3G>A</sup> lines show abundant hyperphosphorylated tau in the hippocampus and entorhinal cortex, but they do not develop seed-competent fibrillar structures. Accumulation of hyperphosphorylated tau was accompanied by neurite degeneration, loss of viable synapses and indicators of behavioral abnormalities. Our results demonstrate that neuronal toxicity can occur in the absence of fibrillar, higher-order structures and that tau hyperphosphorylation is probably involved in the earliest etiological events in tauopathies showing isoform ratio imbalance.
BibTeX
@inproceedings{watamura2024vivo,
  author = {Naoto Watamura and Martha Foiani and Sumi Bez and Mathieu Bourdenx and Alessia Santambrogio and Claire Frodsham and Elena Camporesi and Gunnar Brinkmalm and Henrik Zetterberg and Saisha Patel and Naoko Kamano and Mika Takahashi and Javier Rueda‐Carrasco and Loukia Katsouri and Stephanie L. Fowler and Emir Turkes and Shoko Hashimoto and Hiroki Sasaguri and Takashi Saito and Aditi Islam and Seico Benner and Toshihiro Endo and Katsuji Kobayashi and Chiho Ishida and Michele Vendruscolo and Masahito Yamada and Karen Duff and Takaomi C. Saido},
  title = {{In vivo hyperphosphorylation of tau is associated with synaptic loss and behavioral abnormalities in the absence of tau seeds}},
  booktitle = {Nature Neuroscience},
  year = {2024},
  doi = {10.1038/s41593-024-01829-7},
}
Figure